{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:50:19Z","timestamp":1789775419696,"version":"4.0.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.juro.2015.11.065","type":"journal-article","created":{"date-parts":[[2015,12,12]],"date-time":"2015-12-12T18:34:46Z","timestamp":1449945286000},"page":"1825-1829","source":"Crossref","is-referenced-by-count":23,"title":["Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial"],"prefix":"10.1097","volume":"195","author":[{"given":"Steven A.","family":"Kaplan","sequence":"first","affiliation":[{"name":"Department of Urology, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Arkansas for Medical Sciences, Little Rock, Arkansas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G.","family":"Meehan","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Kusek","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2015.11.065_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1517\/14740338.2013.742885","article-title":"Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation","volume":"12","author":"Gur","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.juro.2015.11.065_bib2","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2015.11.065_bib3","unstructured":"Food and Drug Administration: HYTRIN\u2014terazosin hydrochloride tablet: Abbott Laboratories, 2009. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/019057s022lbl.pdf. Accessed November 5, 2015."},{"key":"10.1016\/j.juro.2015.11.065_bib4","unstructured":"Food and Drug Administration: Highlights of Prescribing Information: Flomax\u00ae (tamsulosin hydrochloride) Capsules, 0.4 mg, 2011. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020579s027lbl.pdf. Accessed November 5, 2015."},{"key":"10.1016\/j.juro.2015.11.065_bib5","unstructured":"Food and Drug Administration: Highlights of Prescribing Information: CARDURA\u00ae XL (doxazosin mesylate extended release tablets). Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021269s017lbl.pdf. Accessed November 5, 2015."},{"key":"10.1016\/j.juro.2015.11.065_bib6","series-title":"Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia","first-page":"523","article-title":"Surgery","author":"Bruskewitz","year":"1997"},{"key":"10.1016\/j.juro.2015.11.065_bib7","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1001\/jama.1988.03720200040030","article-title":"Symptom status and quality of life following prostatectomy","volume":"259","author":"Fowler","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2015.11.065_bib8","unstructured":"Food and Drug Administration: Highlights of Prescribing Information: AVODART (dutasteride) Soft Gelatin Capsules, 2011. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021319s023s025lbl.pdf. Accessed November 5, 2015."},{"key":"10.1016\/j.juro.2015.11.065_bib9","unstructured":"Food and Drug Administration: Highlights of Prescribing Information: PROSCAR\u00ae (finasteride) Tablets, 2014. Available at http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020180s044lbl.pdf. Accessed November 5, 2015."},{"issue":"suppl.","key":"10.1016\/j.juro.2015.11.065_bib10","first-page":"S122","article-title":"BPH: epidemiology and comorbidities","volume":"12","author":"McVary","year":"2006","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.juro.2015.11.065_bib11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group","volume":"338","author":"McConnell","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2015.11.065_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0090-4295(94)80008-1","article-title":"Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis","volume":"44","author":"Lowe","year":"1994","journal-title":"Urology"},{"key":"10.1016\/j.juro.2015.11.065_bib13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00007611-199705000-00009","article-title":"Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia","volume":"90","author":"McKiernan","year":"1997","journal-title":"South Med J"},{"key":"10.1016\/j.juro.2015.11.065_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0090-4295(99)80409-9","article-title":"The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group","volume":"47","author":"Roehrborn","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.juro.2015.11.065_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","article-title":"Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial","volume":"61","author":"Kirby","year":"2003","journal-title":"Urology"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534715053677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534715053677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2015.11.065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T03:54:12Z","timestamp":1651204452000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2015.11.065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1016\/j.juro.2015.11.065"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2015.11.065","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}